Biopharma companies must increasingly adopt creative dealmaking, new digital technologies and early cost effectiveness strategies, all while speeding up the R&D process. This requires a novel way of thinking about partnerships and pipeline strategies, from the highest levels of biopharma leadership.
The 2nd annual FierceBiotech Drug Development Forum will draw together the industry鈥檚 executive decision-makers, to help guide your companies to success throughout the entire life cycle 鈥� both for products and for companies themselves.
This event gives biopharma leaders the skills to improve their partnership strategies with larger companies, financing sources and outsourced research partners. Our experienced and savvy executive-level speaking faculty will help you
shape, select and pitch the best partnerships for drug development, while successfully navigating the financial and regulatory changes arising from a new administration.
Target your learning opportunities toward four full-length tracks:
- STRATEGIC DEAL-MAKING: Develop novel deal structures, improve VC relationships, assess the M&A landscape and cope with a weak IPO market
- CLINICAL RESEARCH OUTSOURCING & TECHNOLOGY: Ensure success in highly partnered business models and move quickly from preclinical to clinical development, by streamlining relationships with your CROs
- IMPROVING R&D OUTCOMES: Step up R&D productivity through better patient engagement and recruiting, while demonstrating differentiation and value for demanding payers and physicians
- DIGITAL TECHNOLOGY & REAL-WORLD EVIDENCE: Use wearables, biomarkers and other technologies to accelerate clinical development and generate real-world evidence for the new health data ecosystem
The 2nd annual FierceBiotech Drug Development Forum will draw together the industry鈥檚 executive decision-makers, to help guide your companies to success throughout the entire life cycle 鈥� both for products and for companies themselves.
This event gives biopharma leaders the skills to improve their partnership strategies with larger companies, financing sources and outsourced research partners. Our experienced and savvy executive-level speaking faculty will help you
shape, select and pitch the best partnerships for drug development, while successfully navigating the financial and regulatory changes arising from a new administration.
Target your learning opportunities toward four full-length tracks:
- STRATEGIC DEAL-MAKING: Develop novel deal structures, improve VC relationships, assess the M&A landscape and cope with a weak IPO market
- CLINICAL RESEARCH OUTSOURCING & TECHNOLOGY: Ensure success in highly partnered business models and move quickly from preclinical to clinical development, by streamlining relationships with your CROs
- IMPROVING R&D OUTCOMES: Step up R&D productivity through better patient engagement and recruiting, while demonstrating differentiation and value for demanding payers and physicians
- DIGITAL TECHNOLOGY & REAL-WORLD EVIDENCE: Use wearables, biomarkers and other technologies to accelerate clinical development and generate real-world evidence for the new health data ecosystem
